The Technical Analyst
Syndax Pharmaceuticals [SNDX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Syndax Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.15% $20.52
America/New_York / 19 apr 2024 @ 15:06
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 743.49 mill |
| EPS: | -2.98 |
| P/E: | -6.89 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 84.97 mill |
| Avg Daily Volume: | 1.177 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.89 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.17x |
| Company: PE -6.89 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.17 (-79.66%) $-16.35 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 19.32 - 21.68 ( +/- 5.76%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-07 | Metzger Michael A | Buy | 214 500 | Stock Options (Right to buy) |
| 2024-02-07 | Metzger Michael A | Buy | 39 000 | Common Stock |
| 2024-02-07 | Metzger Michael A | Buy | 107 250 | Common Stock |
| 2024-02-07 | Goldan Keith A. | Buy | 70 000 | Stock Options (Right to buy) |
| 2024-02-07 | Goldan Keith A. | Buy | 11 700 | Common Stock |
| INSIDER POWER |
|---|
| 45.96 |
| Last 97 transactions |
| Buy: 2 711 593 | Sell: 1 085 664 |
Forecast:
16:00 - $20.56
Live Trading Signals (every 1 min)
Forecast
1: 15:15 - $20.57
Forecast 2: 16:00 - $20.56
Forecast 3: 16:00 - $20.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $20.52 (0.15% ) |
| Volume | 0.382 mill |
| Avg. Vol. | 1.177 mill |
| % of Avg. Vol | 32.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SNDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $22.15 | N/A | Active |
|---|
SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Latest Press Releases
2024-04-10 16:05:00 - Press Release
Syndax Announces Participation At The Stifel 2024 Virtual Targeted Oncology Forum
Waltham, mass. , april 10, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that michael a.
2024-04-08 07:00:00 - Press Release
Syndax Presents Positive Pediatric Data From Pivotal Augment-101 Trial Of Revumenib In Relapsed/refractory Kmt2ar Acute Leukemia At Aspho Plenary Session
– consistent safety and efficacy profiles across adult and pediatric populations – – majority of pediatric patients who achieved an overall response proceeded to transplant; patients receiving post-transplant revumenib maintenance remained in remission as of data cutoff date – – no treatment-related discontinuations or dose reductions – waltham, mass. , april 8, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of positive data from the pivotal augment-101 trial in pediatric patients with relapsed/refractory (r/r) kmt2a-rearranged (kmt2ar) acute myeloid leukemia (aml) and acute lymphoid leukemia (all) treated with revumenib, a first-in-class menin inhibitor.
2024-04-05 16:05:00 - Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass. , april 5, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on april 1, 2024 the company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the company's 2023 inducement plan.
2024-03-28 07:00:00 - Press Release
Syndax Announces Completion Of Enrollment In Augment-101 Pivotal Trial Cohort Of Patients With Relapsed/refractory Mnpm1 Acute Myeloid Leukemia
– topline data expected in 4q24 could support snda filing in 1h25 – – revumenib has the potential to address $2 billion mnpm1 and kmt2ar r/r acute leukemia u.s. market opportunity – waltham, mass. , march 28, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced completion of enrollment in the augment-101 pivotal trial cohort of patients with relapsed/refractory (r/r) mutant nucleophosmin (mnpm1) acute myeloid leukemia (aml).
2024-03-26 16:05:00 - Press Release
Syndax Announces Fda Priority Review Of Nda For Revumenib For The Treatment Of Relapsed/refractory Kmt2ar Acute Leukemia
– pdufa action date set for september 26, 2024 – – nda being reviewed under fda's rtor program – waltham, mass., march 26, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the u.s. food and drug administration (fda) has granted priority review for its new drug application (nda) for revumenib, the company's first-in-class menin inhibitor, for the treatment of adult and pediatric relapsed or refractory (r/r) kmt2a-rearranged (kmt2ar) acute leukemia.
Latest News
2024-04-03 13:47:03 - CNBC Television
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
2024-03-28 10:56:13 - Zacks Investment Research
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
2024-02-27 21:21:05 - Seeking Alpha
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript
2024-02-26 09:51:10 - Zacks Investment Research
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2023-11-02 21:26:05 - Seeking Alpha
Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript
2023-10-13 14:52:22 - Seeking Alpha
Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the current standard of care. It is expected that an NDA of revumenib for AML is expected before end of 2023; it is also being evaluated in other patient populations which could expand its potential.
2023-10-02 09:22:00 - Proactive Investors
Syndax Pharmaceuticals fall despite positive leukemia
Syndax Pharmaceuticals (NASDAQ:SNDX) Inc (Syndax Pharmaceuticals (NASDAQ:SNDX)) stock was on the back foot on Monday, after reporting results from a leukaemia drug trial which met its primary endpoint. "We are thrilled to report positive results for revumenib in KMT2Ar acute leukaemia that demonstrate the utility of its practice-changing clinical profile and highlight revumenib's potential as a first- and best-in-class agent," chief executive Michael Metzger said.
2023-10-02 05:41:00 - Market Watch
SmileDirectClub shares plunge after bankruptcy filing, with Syndax and AMC shares climbing and other active stocks
Syndax Pharmaceuticals Inc. SNDX, -7.10% rose 19% in premarket trading. The clinical stage biopharmaceutical company said late Friday that it would release topline results from its trial of Revumenib to treat certain forms of leukemia.
2023-09-29 16:05:00 - PRNewsWire
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
WALTHAM, Mass. , Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Monday, October 2, 2023 at 8:00 a.m.
2023-09-08 10:42:03 - Seeking Alpha
Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an increase in operating expenses in Q2 2023, but remains financially stable with cash reserves of $418.3 million. Syndax has two leading candidates in its drug pipeline, revumenib and axatilimab, which show promise in treating acute leukemia and chronic graft-versus-host disease (cGVHD) respectively.